Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor?

Research output: Contribution to journalArticle

Standard

Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor? / Chung, NA; Belgore, F; Li-Saw-Hee, FL; Conway, Dwayne; Blann, Andrew; Lip, Gregory.

In: Blood Coagulation and Fibrinolysis, Vol. 33, No. 9, 01.09.2002, p. 2187-91.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{f8d6fda584e54ab6993ee8d05ac9ada5,
title = "Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor?",
abstract = "BACKGROUND AND PURPOSE: Tissue factor (TF; an initiator of coagulation) and vascular endothelial growth factor (VEGF; a marker of angiogenesis) are involved in the hypercoagulable state associated with malignancy. We investigated their roles in chronic atrial fibrillation (AF), a condition also associated with increased risk of stroke and thromboembolism, as well as a prothrombotic or hypercoagulable state. METHODS: We studied 25 patients with AF (20 men; mean+/-SD age, 62+/-13 years) who were compared with 2 control groups in sinus rhythm: 30 healthy control subjects (17 men; mean age, 60+/-9 years) and 35 patient control subjects with coronary artery disease (CAD; 27 men; mean age, 60+/-12 years). Plasma levels of TF, VEGF, and the VEGF receptor sFlt-1 were measured by enzyme-linked immunosorbent assay. RESULTS: VEGF, sFlt-1, and TF were significantly different between the 3 groups, with abnormal levels in AF and CAD patients compared with control subjects (P",
author = "NA Chung and F Belgore and FL Li-Saw-Hee and Dwayne Conway and Andrew Blann and Gregory Lip",
year = "2002",
month = sep,
day = "1",
language = "English",
volume = "33",
pages = "2187--91",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

RIS

TY - JOUR

T1 - Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor?

AU - Chung, NA

AU - Belgore, F

AU - Li-Saw-Hee, FL

AU - Conway, Dwayne

AU - Blann, Andrew

AU - Lip, Gregory

PY - 2002/9/1

Y1 - 2002/9/1

N2 - BACKGROUND AND PURPOSE: Tissue factor (TF; an initiator of coagulation) and vascular endothelial growth factor (VEGF; a marker of angiogenesis) are involved in the hypercoagulable state associated with malignancy. We investigated their roles in chronic atrial fibrillation (AF), a condition also associated with increased risk of stroke and thromboembolism, as well as a prothrombotic or hypercoagulable state. METHODS: We studied 25 patients with AF (20 men; mean+/-SD age, 62+/-13 years) who were compared with 2 control groups in sinus rhythm: 30 healthy control subjects (17 men; mean age, 60+/-9 years) and 35 patient control subjects with coronary artery disease (CAD; 27 men; mean age, 60+/-12 years). Plasma levels of TF, VEGF, and the VEGF receptor sFlt-1 were measured by enzyme-linked immunosorbent assay. RESULTS: VEGF, sFlt-1, and TF were significantly different between the 3 groups, with abnormal levels in AF and CAD patients compared with control subjects (P

AB - BACKGROUND AND PURPOSE: Tissue factor (TF; an initiator of coagulation) and vascular endothelial growth factor (VEGF; a marker of angiogenesis) are involved in the hypercoagulable state associated with malignancy. We investigated their roles in chronic atrial fibrillation (AF), a condition also associated with increased risk of stroke and thromboembolism, as well as a prothrombotic or hypercoagulable state. METHODS: We studied 25 patients with AF (20 men; mean+/-SD age, 62+/-13 years) who were compared with 2 control groups in sinus rhythm: 30 healthy control subjects (17 men; mean age, 60+/-9 years) and 35 patient control subjects with coronary artery disease (CAD; 27 men; mean age, 60+/-12 years). Plasma levels of TF, VEGF, and the VEGF receptor sFlt-1 were measured by enzyme-linked immunosorbent assay. RESULTS: VEGF, sFlt-1, and TF were significantly different between the 3 groups, with abnormal levels in AF and CAD patients compared with control subjects (P

M3 - Article

C2 - 12215585

VL - 33

SP - 2187

EP - 2191

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 9

ER -